|
|
LETTERS TO EDITOR |
|
Year : 2016 | Volume
: 5
| Issue : 1 | Page : 63-64 |
|
Comparative lipid profile of Type 2 obese diabetics and obese nondiabetics: A hospital based study from hilly terrains of Mandi, Himachal Pradesh
Rohit Sharma1, Hetal Amin2, Prajapati Pradeep Kumar3
1 Department of Rasashastra and Bhaishajya Kalpana, Abhilashi Ayurvedic College and Research Institute, Abhilashi University, Mandi, Himachal Pradesh, India 2 Department of Basic Principles, Parul Institute of Ayurveda, Vadodara, Gujarat, India 3 Department of Rasashastra and Bhaishajya Kalpana, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India
Date of Web Publication | 13-Jan-2016 |
Correspondence Address: Rohit Sharma Department of Rasashastra and Bhaishajya Kalpana, Abhilashi Ayurvedic College and Research Institute, Abhilashi University, Chail Chowk, Mandi - 175 028, Himachal Pradesh India
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/2278-344X.173876
How to cite this article: Sharma R, Amin H, Kumar PP. Comparative lipid profile of Type 2 obese diabetics and obese nondiabetics: A hospital based study from hilly terrains of Mandi, Himachal Pradesh. Int J Health Allied Sci 2016;5:63-4 |
How to cite this URL: Sharma R, Amin H, Kumar PP. Comparative lipid profile of Type 2 obese diabetics and obese nondiabetics: A hospital based study from hilly terrains of Mandi, Himachal Pradesh. Int J Health Allied Sci [serial online] 2016 [cited 2024 Mar 29];5:63-4. Available from: https://www.ijhas.in/text.asp?2016/5/1/63/173876 |
Sir,
Type 2 diabetes mellitus (T2DM) is an independent risk factor for coronary artery disease, and risk of coronary disease is 3- to 4-fold increased in patients with diabetes compared with a nondiabetic population,[1],[2],[3] and 60–80% of T2DM patients are obese.[4] The pathophysiological pathways linking obesity and T2DM is ascertained across numerous studies in different populations.[5],[6],[7] Dyslipidemia, for which body mass index (BMI) is a relatively accurate surrogate, has been linked to profound endocrine changes related to T2DM.[8] Beside T2DM, obese people are at increased risk of coronary artery disease, and hypertension.[8],[9],[10]
Mandi region is located in the North-Western Himalayan range of Himachal Pradesh. Reports on lipid profile and co-morbidity of diabetes and obesity as a risk factor for cardiovascular diseases among the diabetic population in Mandi are lacking. This study was therefore conducted to examine the lipid profile in obese T2DM patients and obese control group to correlate coronary heart disease with dyslipidemia among residents of Mandi. The present study was conducted in under-graduate teaching and research hospital of Abhilashi University, Mandi, from January 1, 2015 to July 7, 2015. The study was conducted to assess the lipid profile in randomly selected 102 T2DM patients associated with obesity and 68 obese age- and sex-matched controls, residing in urban and rural areas of Jamnagar. Venous blood samples were taken from all the subjects in the morning after fasting overnight. Plasma levels of total cholesterol, triglycerides, high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C) were analyzed. Total cholesterol and triglycerides concentration were determined with the semi-automated enzymatic analyzer. Serum HDL-C level was measured by phospho-tungstate precipitation method.[11] Serum LDL-C was calculated according to computational procedures of Friedewald et al.[12]Inclusion criteria: Known T2DM patients with BMI more than 30 kg/m 2 were included in this study. Exclusion criteria included pregnancy, chronic infectious disease, heart failure, renal failure, and drug allergy (confirmed from the subject's personal physician report and a detailed). Ethical approval for the study was taken from the Institutional Research Ethical Committee. The obtained data was analyzed statistically using IBM SPSS statistics software version 22.0 (IBM Corp., Armonk, NY, USA, Released 2013); t-test was used to observe the relationship between different variables, and the significance level was set at P < 0.05. The obtained results were interpreted as: P < 0.001 as highly significant, P < 0.05 or P < 0.01 as significant, and P < 0.10 as insignificant.
The mean ± standard deviation (SD) age (years) of diabetic patients with obesity was 53.42 ± 2.10 while the mean ± SD age of control was 50.37 ± 3.08. Out of 102 patients, 57 (55.88%) were males and 45 (44.11%) were females. Among control subjects, 44 (64.70%) were males and 24 (35.29%) were females. The obtained results (in mean ± SD) were as follows: Total cholesterol (mg/dl) was 229.31 ± 28.06 in obese diabetics and 158.42 ± 37.55 in obese controls. Serum triglyceride (mg/dl) was 201.67 ± 41.28 in obese diabetics and 112.10 ± 27.19 in obese controls. Serum HDL-C (mg/dl) was 35.44 ± 10.68 in obese diabetics and 43.54 ± 14.17 in obese controls. Serum LDL-C (mg/dl) was 151.44 ± 39.10 in obese diabetics and 83.26 ± 31.08 in obese controls. Lipid profile of obese T2DM patients when compared to obese control subjects showed statistically significant increase in the levels of serum total cholesterol (P< 0.001), serum triglycerides (P< 0.001), serum LDL-C (P< 0.001) while serum HDL-C levels did not show statistically significant difference in the two group (P > 0.05). Previous studies have shown similar results as were obtained in our study.[13],[14],[15]
Though the study was of limited sample size, the findings reflect that the obese diabetic individuals have dyslipidemia and are at higher risk to develop cardiovascular diseases. The pathophysiological processes involved in the development of these complications in obese diabetics are well recognized by recent works.[16],[17] Further, well-stratified studies covering larger population are requisite in this direction to identify some potential modifying factors (viz., duration of obesity, body fat distribution, physical activity, diet, and genetics/ethnicity) that make such diabetes-obesity association complex and multifactorial. The present study also proposes to adopt suitable dietary and lifestyle guidelines to arrest or delay the far-reaching ominous complications of Type 2 diabetes.[18],[19]
Financial support and sponsorship
Abhilashi University, Chail Chowk, Mandi, Himachal Pradesh.
Conflicts of interest
There are no conflicts of interest.
References | | |
1. | Kalofoutis C, Piperi C, Kalofoutis A, Harris F, Phoenix D, Singh J. Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. Exp Clin Cardiol 2007;12:17-28. |
2. | Naito R, Kasai T. Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives. World J Cardiol 2015;7:119-24. |
3. | Sarkar NC, Jain S, Sarkar P, Tilkar M, Modi N. Early detection of coronary artery disease in asymptomatic type 2 diabetes mellitus patients. Int J Adv Med 2015;2:26-9. |
4. | Sheth JJ. Diabetes, microalbuminuria and hypertension. Clin Exp Hypertens 1999;21:61-8. |
5. | Al-Quwaidhi AJ, Pearce MS, Critchley JA, O'Flaherty M. Obesity and type 2 diabetes mellitus: A complex association. Saudi J Obes 2013;1:49-56. |
6. | Lazar MA. How obesity causes diabetes: Not a tall tale. Science 2005;307:373-5. |
7. | Ahima RS. Revisiting leptin's role in obesity and weight loss. J Clin Invest 2008;118:2380-3. |
8. | Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003;115 Suppl 8A: 37S-41S. |
9. | Gough SC, Kragh N, Ploug UJ, Hammer M. Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England. Diabetes Metab Syndr Obes 2009;2:179-84. |
10. | Toth PP. Effective management of the type 2 diabetes patient with cardiovascular and renal disease: Secondary prevention strategies after a myocardial infarction. Curr Diabetes Rev 2012;8:219-28. |
11. | Demacker PN, Hessels M, Toenhake-Dijkstra H, Baadenhuijsen H. Precipitation methods for high-density lipoprotein cholesterol measurement compared, and final evaluation under routine operating conditions of a method with a low sample-to-reagent ratio. Clin Chem 1997;43:663-8. |
12. | Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502. |
13. | Cohen AM, Fidel J, Cohen B, Furst A, Eisenberg S. Diabetes, blood lipids, lipoproteins, and change of environment: Restudy of the “new immigrant Yemenites” in Israel. Metabolism 1979;28:716-28. |
14. | Bijlani PK, Shah K, Raheja BS, Krishnaswamy PR. High density lipoprotein cholesterol in diabetes. J Assoc Physicians India 1984;32:309-11. |
15. | Zargar AH, Wandroo FA, Wadhwa MB, Laway BA, Masoodi SR, Shah NA. Serum lipid profile in non-insulin-dependent diabetes mellitus associated with obesity. Int J Diabetes Dev Ctries 1995;15:9-13. |
16. | Gambhir JK, Kaur H, Gambhir DS, Prabhu KM. Lipoprotein (a) as an independent risk factor for coronary artery disease in patients below 40 years of age. Indian Heart J 2000;52:411-5. |
17. | Yadav NK, Thanpari C, Shrewastwa MK, Mittal RK. Comparison of lipid profile in type-2 obese diabetics and obese non-diabetic individuals. A hospital based study from Western Nepal. Kathmandu Univ Med J (KUMJ) 2012;10:44-7. |
18. | Sharma R, Prajapati PK. Diet and lifestyle guidelines for diabetes: Evidence based ayurvedic perspective. Rom J Diabetes Nutr Metab Dis 2014;21:335-46. |
19. | Sharma R, Amin H, Prajapati PK. Yoga: As an adjunct therapy to trim down the ayurvedic drug requirement in non insulin-dependent diabetes mellitus. Anc Sci Life 2014;33:229-35. |
This article has been cited by | 1 |
Adjunct use of honey in diabetes mellitus: A consensus or conundrum? |
|
| Rohit Sharma,Natália Martins,Ashun Chaudhary,Neha Garg,Vineet Sharma,Kamil Kuca,Eugenie Nepovimova,Hardeep Singh Tuli,Anupam Bishayee,Anand Chaudhary,Pradeep Kumar Prajapati | | Trends in Food Science & Technology. 2020; 106: 254 | | [Pubmed] | [DOI] | | 2 |
Nutraceuticals in the management of diabetes mellitus |
|
| Vrish Dhwaj Ashwlayan, Saurabh Nimesh | | Pharmacy & Pharmacology International Journal. 2018; 6(2) | | [Pubmed] | [DOI] | |
|
|
|
|